Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMPOEK)

Drug Name

alpha-ergocryptine Drug Info

Synonyms

Ergocryptine; alpha-Ergocryptine; Ergocryptine-alpha; 511-09-1; UNII-6WFB60157B; alpha-Ergokryptine; NSC 169479; CHEMBL1403281; CHEBI:10276; YDOTUXAWKBPQJW-NSLWYYNWSA-N; 12'-Hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione; 6WFB60157B; EINECS 208-121-2; 12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)ergotaman-3',6',18-trione; 12'-hydroxy-5'alpha-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman; BRN 0078810; 12'-Hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotaman-3',6',18-trione

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 134551
ChEBI ID: CHEMBL10276
CAS Number: CAS 511-09-1
TTD Drug ID: DMMPOEK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 6 receptor (HTR6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LU AE58054	DMWGRQD	Schizophrenia	6A20	Phase 3	[3]
SB-742457	DM6L4ZT	Alzheimer disease	8A20	Phase 3	[4]
AVN 211	DMVB4OS	Schizophrenia	6A20	Phase 2/3	[5]
SYN120	DMDF7XB	Parkinson disease	8A00.0	Phase 2	[6]
AVN 101	DMJFLBC	Alzheimer disease	8A20	Phase 2	[5]
SYN-120	DMPW0UL	Alzheimer disease	8A20	Phase 2	[7]
PF-05212377	DMPVQYR	Alzheimer disease	8A20	Phase 2	[8]
AVN 322	DMK2LGM	Cognitive impairment	6D71	Phase 2	[4]
SAM-531	DMHVJZ6	Alzheimer disease	8A20	Phase 2	[9]
SUVN-502	DMQD753	Alzheimer disease	8A20	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 6 receptor (HTR6)	TTJS8PY	5HT6R_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 271).
2	Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem. 1998 Nov;71(5):2169-77.
3	Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
4	5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
5	Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
6	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
7	The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
8	PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
9	Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
10	Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.